141 related articles for article (PubMed ID: 1697561)
1. Homologous species restriction of the complement-mediated killing of nucleated cells.
Yamamoto H; Blaas P; Nicholson-Weller A; Hänsch GM
Immunology; 1990 Aug; 70(4):422-6. PubMed ID: 1697561
[TBL] [Abstract][Full Text] [Related]
2. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.
Schönermark S; Rauterberg EW; Shin ML; Löke S; Roelcke D; Hänsch GM
J Immunol; 1986 Mar; 136(5):1772-6. PubMed ID: 2419413
[TBL] [Abstract][Full Text] [Related]
3. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
Rollins SA; Zhao J; Ninomiya H; Sims PJ
J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
[TBL] [Abstract][Full Text] [Related]
5. Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.
Hänsch GM; Schönermark S; Roelcke D
J Clin Invest; 1987 Jul; 80(1):7-12. PubMed ID: 3597779
[TBL] [Abstract][Full Text] [Related]
6. The C8-binding protein of human erythrocytes: interaction with the components of the complement-attack phase.
Schönermark S; Filsinger S; Berger B; Hänsch GM
Immunology; 1988 Apr; 63(4):585-90. PubMed ID: 3366469
[TBL] [Abstract][Full Text] [Related]
7. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
8. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
9. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.
Mäenpää A; Junnikkala S; Hakulinen J; Timonen T; Meri S
Am J Pathol; 1996 Apr; 148(4):1139-52. PubMed ID: 8644856
[TBL] [Abstract][Full Text] [Related]
10. Expression of the complement regulator factor C8 binding protein on human glomerular cells protects them from complement-mediated killing.
Schieren G; Schönermark M; Braunger M; Hänsch GM
Exp Nephrol; 1994; 2(5):299-305. PubMed ID: 7812736
[TBL] [Abstract][Full Text] [Related]
11. Paroxysmal nocturnal hemoglobinuria. Enhanced stimulation of platelets by the terminal complement components is related to the lack of C8bp in the membrane.
Blaas P; Berger B; Weber S; Peter HH; Hänsch GM
J Immunol; 1988 May; 140(9):3045-51. PubMed ID: 3361126
[TBL] [Abstract][Full Text] [Related]
12. Purification and characterization of decay-accelerating factor (DAF) from Raji cells.
Fujita T; Shinkai Y; Inoue T; Tamura N
Immunology; 1988 Jul; 64(3):369-74. PubMed ID: 2457546
[TBL] [Abstract][Full Text] [Related]
13. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
14. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor.
Charreau B; Cassard A; Tesson L; Le Mauff B; Navenot JM; Blanchard D; Lublin D; Soulillou JP; Anegon I
Transplantation; 1994 Dec; 58(11):1222-9. PubMed ID: 7527603
[TBL] [Abstract][Full Text] [Related]
15. Characterization of rabbit complement component C8. Functional evidence for the species-selective recognition of C8 alpha by homologous restriction factor (CD59).
White RV; Kaufman KM; Letson CS; Platteborze PL; Sodetz JM
J Immunol; 1994 Mar; 152(5):2501-8. PubMed ID: 7510745
[TBL] [Abstract][Full Text] [Related]
16. Anti-idiotypic antibodies derived against C8, C9 and perforin bind homologous restriction factor.
Young JD; Jiang S; Liu CC; Hasselkus-Light CS
J Immunol Methods; 1990 Mar; 128(1):133-42. PubMed ID: 1691232
[TBL] [Abstract][Full Text] [Related]
17. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
[TBL] [Abstract][Full Text] [Related]
18. Decay accelerating factor regulates complement activation on glomerular epithelial cells.
Quigg RJ; Nicholson-Weller A; Cybulsky AV; Badalamenti J; Salant DJ
J Immunol; 1989 Feb; 142(3):877-82. PubMed ID: 2464030
[TBL] [Abstract][Full Text] [Related]
19. Distinct restriction of complement- and cell-mediated lysis.
Hollander N; Shin ML; Rosse WF; Springer TA
J Immunol; 1989 Jun; 142(11):3913-6. PubMed ID: 2785570
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of the complement-regulatory factor C8 binding protein (C8bp) on U937 cells after stimulation with IL-1 beta, endotoxin, IFN-gamma, or phorbol ester.
Schieren G; Janssen O; Hänsch GM
J Immunol; 1992 May; 148(10):3183-8. PubMed ID: 1578143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
